<DOC>
	<DOCNO>NCT00378573</DOCNO>
	<brief_summary>This Phase II prospective , multicenter study evaluate Progression Free Survival ( PFS ) first line treatment combination gemcitabine , docetaxel , bevacizumab subject advance metastatic Non-Small Cell Lung Cancer ( NSCLC ) . PFS measure date registration ( ie , assignment subject number subject meet entry criterion ) early date document evidence progressive disease , date death due cause , whichever occur first .</brief_summary>
	<brief_title>Multicenter Evaluation Docetaxel , Gemcitabine , Bevacizumab Combination Followed Bevacizumab Alone Subjects With Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . 1 . Histologic cytologic confirmation locally advance ( pleural effusion ) metastatic ( Stage IIIB/IV ) NSCLC ( nonsquamouscell histology ) , mixed tumor type select base predominant cell type unless small cell element discover ( case subject eligible ) ; 2 . Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; /= 20 mm conventional computerize tomography ( CT ) magnetic resonance imaging ( MRI ) scan , &gt; /= 10 mm spiral computerize tomography ( CT ) scan 3 . No previous systemic chemotherapy 4 . Estimated life expectancy &gt; /= 12 week 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 2 6 . Nonpregnant , nonlactating female subject ; male female subject childbearing potential must willing use effective form contraception therapy 90 day thereafter ; effective form contraception define oral contraceptive double barrier method ; pregnancy determined/ rule use serum human chorionic gonadotropin ( HCG ) 7 . Subjects must adequate renal function determine follow within 1 week prior study registration : Calculated creatinine clearance &gt; 45 mL/min use CockcroftGault formula ; Urine protein : creatinine ( UPC ) ratio &lt; 1.0 spot urinalysis ; Urine dipstick protein &lt; 2+ ( subject discover &gt; = 2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate &lt; /= 1 g protein 24 hour eligible ) ; 8 . Hematologic evaluation within 2 week prior study registration ( minimum value ) : Absolute neutrophil count ( ANC ) &gt; /= 1500 mm3 ; Platelet count &gt; /= 100,000 mm3 ; Hemoglobin ( Hg ) &gt; /= 9.9 g/dL ( erythropoietin may transfuse maintain exceed level ) ; Partial thromboplastin time ( PTT ) great upper limit normal ( ULN ) 9 . Hepatic function evaluation within 2 week prior study registration ( detailed protocol provide Investigator ) : Total bilirubin &lt; /= upper limit normal ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase must within range allow eligibility ; In determine eligibility abnormal two value ( AST ALT ) use ( detail decision full protocol provide Investigator ) 1 . Receipt prior systemic chemotherapy , vascular endothelial growth factor ( VEGF ) endothelial growth factor receptor ( EGFR ) inhibitor therapy time ; receipt recent current radiation therapy ; current , recent ( within 4 week prior study registration ) , plan receipt investigational therapy ( investigational therapy define treatment currently regulatory authority approve indication ) 2 . Subjects cardiovascular disease related treatment 3 . Surgical procedure anamnesis ( medical history ) : Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior registration , anticipation need major surgical procedure course study ; Minor surgical procedure ( eg , fine needle aspiration , core biopsy ) within 7 day prior registration ; 4 . Serious nonhealing wound , ulcer , bone fracture ; 5 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study registration ; 6 . History gross hemoptysis ( define bright red blood &gt; /= 0.5 teaspoon ) 7 . History hypersensitivity reaction drug formulate polysorbate 80 ; 8 . Subjects brain metastasis ; 9 . Peripheral neuropathy &gt; /= Grade 2 ( base Common Toxicity Criteria Adverse Event [ CTCAE ] v3.0 ) ; 10 . History malignancy NSCLC ; exception include : Curatively treat basal cell carcinoma ; cervical intraepithelial neoplasia ; localize prostate cancer current prostatespecific antigen ( PSA ) &lt; 1.0 ng/dL 2 successive evaluation least 3 month apart , recent evaluation within 4 week study registration ; History another malignancy curatively treat evidence disease minimum 5 year ; 11 . Symptoms clinically meaningful illness 90 day study , history disease , ( human immunodeficiency virus ( HIV ) positive , chronic infection ( eg , pulmonary tuberculosis ) , hepatitis A , B C ( active previously treat ) , active infection fever , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication ; ( test condition investigator discretion ) 12 . Mental condition render subject unable understand nature , scope , possible consequence study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>